Wednesday, August 15, 2012
Soricimed Biopharma Inc., of Toronto, initiated the Phase I trial of its anticancer agent SOR-C13. The multicenter, open-label, dose-escalation study is designed to assess safety and tolerability in patients with advanced cancer tumors, with a weighting on ovarian cancers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.